LQDA
Liquidia Corp Ordinary Shares
North American company
Healthcare
Biotechnology
/
NAV Price
-
Last Traded
-
Chg
-
-
XNAS
-
Updated: -
Times are shown in GMT-5, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
This stock can be held in:
/
Company Profile
Liquidia Corp, formerly Liquidia Technologies Inc is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain.
NASDAQ:LQDA
US53635D2027
USD
Loading Comparison
Latest LQDA News
Currently there are no news & analysis articles for this instrument. Visit our news hub for the latest investment news from ii and Alliance News